ROBESTI, DANIELE
 Distribuzione geografica
Continente #
EU - Europa 665
NA - Nord America 548
AS - Asia 478
SA - Sud America 87
Continente sconosciuto - Info sul continente non disponibili 55
AF - Africa 14
Totale 1.847
Nazione #
US - Stati Uniti d'America 509
RU - Federazione Russa 378
SG - Singapore 158
CN - Cina 141
IT - Italia 132
BR - Brasile 62
VN - Vietnam 51
HK - Hong Kong 42
BD - Bangladesh 34
DE - Germania 28
GB - Regno Unito 22
FR - Francia 21
FI - Finlandia 18
SE - Svezia 18
CA - Canada 17
ES - Italia 14
NL - Olanda 13
IN - India 12
MX - Messico 11
AR - Argentina 7
IQ - Iraq 7
JP - Giappone 7
CO - Colombia 6
JM - Giamaica 5
PL - Polonia 5
NG - Nigeria 4
NP - Nepal 4
ZA - Sudafrica 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
CH - Svizzera 3
ID - Indonesia 3
IE - Irlanda 3
SA - Arabia Saudita 3
TR - Turchia 3
VE - Venezuela 3
AT - Austria 2
BB - Barbados 2
CR - Costa Rica 2
DZ - Algeria 2
EC - Ecuador 2
LT - Lituania 2
MY - Malesia 2
UA - Ucraina 2
AL - Albania 1
BE - Belgio 1
BH - Bahrain 1
CL - Cile 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
GT - Guatemala 1
IL - Israele 1
KH - Cambogia 1
LB - Libano 1
MA - Marocco 1
OM - Oman 1
PE - Perù 1
PR - Porto Rico 1
PY - Paraguay 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 1.792
Città #
Singapore 104
Ashburn 83
Moscow 67
San Jose 67
Hong Kong 41
Dallas 39
Milan 32
Beijing 28
New York 24
Shanghai 23
Los Angeles 20
Council Bluffs 18
Rome 14
Hefei 13
Ho Chi Minh City 13
Munich 13
Phoenix 13
Santa Clara 13
Lauterbourg 12
Hanoi 11
Orem 10
Boardman 9
Buffalo 9
Montreal 9
Helsinki 8
Brooklyn 7
Atlanta 6
Frankfurt am Main 6
Guangzhou 6
Tokyo 6
Turku 6
Brescia 5
Chicago 5
Da Nang 5
Denver 5
Erbil 5
Manchester 5
Mexico City 5
São Paulo 5
Turin 5
Valencia 5
Warsaw 5
Amsterdam 4
Chennai 4
Lappeenranta 4
Naples 4
Poplar 4
Toronto 4
Bilbao 3
Bologna 3
Boston 3
Dublin 3
Johannesburg 3
London 3
Modena 3
Monza 3
Nuremberg 3
Paris 3
Pune 3
Rotterdam 3
Seattle 3
Shenzhen 3
Zurich 3
Bergamo 2
Birmingham 2
Bogotá 2
Bridgetown 2
Catania 2
Civita Castellana 2
Cologne 2
Dhaka 2
Genoa 2
Guarulhos 2
Haiphong 2
Holyhead 2
Houston 2
Jeddah 2
Kathmandu 2
Kingston 2
Lagos 2
Lari 2
Lawrence 2
Manassas 2
Miami 2
Milwaukee 2
Mushin 2
Oudehaske 2
Palermo 2
Petrópolis 2
Princeton 2
Queens 2
Querétaro 2
Rancho Cucamonga 2
Rio Claro 2
Stockholm 2
São Luís 2
Tucson 2
Abakan 1
Abu Dhabi 1
Acarigua 1
Totale 925
Nome #
Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysis 151
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis 146
Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of the Memorial Sloan Kettering Cancer Center and Briganti Nomograms and Development of a Novel Tool 137
Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study 131
Defining the optimal target-to-background ratio to identify positive lymph nodes in prostate cancer patients undergoing robot-assisted [99mTc]Tc-PSMA radioguided surgery: updated results and ad interim analyses of a prospective phase II study 130
Variability of mpMRI diagnostic performance according to the upfront individual patient risk of having clinically significant prostate cancer 123
Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters 119
Understanding the Role of Ureteral Access Sheath in Preventing Post-Operative Infectious Complications in Stone Patients Treated with Ureteroscopy and Ho:YAG Laser Lithotripsy: Results from a Tertiary Care Referral Center 118
Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought 117
Immunotherapy in advanced kidney cancer: an alternative meta-analytic method using reconstructed survival data in case of proportional hazard assumption violation 115
External Validation of Nomograms for the Identification of Pelvic Nodal Dissection Candidates Among Prostate Cancer Patients with Negative Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography 110
Ho:YAG laser and temperature: is it safe to use high-power settings? 110
What to expect from the novel pulsed thulium:YAG laser? A systematic review of endourological applications 107
ASSOCIATION BETWEEN POLYMORPHISMS OF HOMOLOGOUS RECOMBINATION RAD51B AND DISEASE RECURRENCE IN A PROSPECTIVE COHORT OF PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY 103
Utility of MRI perilesional biopsy in prostate cancer: impact of the Prostate Imaging-Reporting and Data System and biopsy history 79
Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score 27
The Impact of Second Opinion Expert Pathology Review in Patient Management at the Time of Transurethral Resection of the Bladder 12
Ho: YAG and thulium fiber lasers exhibit comparable temperature distribution: an in vitro evaluation of thermal safety distances for endourological applications—section of EAU endourology 10
Adjuvant pembrolizumab plus belzutifan versus placebo in clear cell renal cell carcinoma: a reconstructed survival data analysis of the KEYNOTE-564 and the LITESPARK-022 trials 2
Totale 1.847
Categoria #
all - tutte 7.795
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.795


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222 0 0 0 0 0 0 0 0 0 0 0 2
2022/202345 5 3 3 7 4 5 3 8 2 1 0 4
2023/2024105 6 2 8 7 8 20 6 23 1 7 5 12
2024/2025272 24 4 9 8 18 35 54 36 25 8 18 33
2025/20261.240 76 69 55 144 117 30 102 124 326 90 66 41
2026/2027182 46 61 69 6 0 0 0 0 0 0 0 0
Totale 1.847